吗啡与P2Y抑制剂在急性冠脉综合征患者中的效应:比较性研究的荟萃分析
该荟萃分析检索三个数据库,纳入14项比较性研究(n=73,033),评估ACS患者抗血小板治疗联用或不联用吗啡的结局。联用与不联用吗啡死亡率无显著差异(RR=1.13,95%CI 0.78至1.64);不联用吗啡显著降低MACE风险(RR=0.78,95%CI 0.67至0.89;I²=0%),但增加大出血风险(POR=1.87,95%CI 1.04至3.35;I²=0%)。作者结论认为,在抗血小板治疗基础上加用吗啡前,临床医生应在较低MACE风险与较高大出血风险之间权衡。
要点
- 14项比较性研究(n=73,033)显示,ACS患者抗血小板治疗联用或不联用吗啡,死亡率无显著差异(RR=1.13,95%CI 0.78至1.64)。
- 不联用吗啡者MACE风险显著低于联用者(RR=0.78,95%CI 0.67至0.89;I²=0%)。
- 不联用吗啡者大出血风险显著高于联用者(POR=1.87,95%CI 1.04至3.35;I²=0%)。
- 作者认为,在抗血小板治疗基础上加用吗啡前,临床医生应在较低MACE风险与较高大出血风险之间权衡。
适用人群与场景
- 急性冠脉综合征(ACS)患者,来自14项比较性研究(n=73,033)。
研究设计与关键结果
- 研究类型为比较性研究的荟萃分析,纳入14项研究(n=73,033),检索三个数据库,采用随机效应模型。
- 抗血小板治疗联用吗啡与不联用吗啡相比,死亡率无显著差异(RR=1.13,95%CI 0.78至1.64)。
- 不联用吗啡者MACE风险显著低于联用者(RR=0.78,95%CI 0.67至0.89;I²=0%)。
- 不联用吗啡者大出血风险显著高于联用者(POR=1.87,95%CI 1.04至3.35;I²=0%)。
证据类型、等级与局限
- 证据类型为比较性研究的荟萃分析;原文未报告证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在抗血小板治疗基础上加用吗啡前,临床医生应在较低MACE风险与较高大出血风险之间进行权衡。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: P2Y inhibitor and morphine are widely used in caring for patients with the acute coronary syndrome (ACS), but there are some concerns about the combination use due to interaction in metabolism. Therefore, this study aimed to examine whether using morphine with antiplatelets in patients with ACS affects the clinical outcomes based on currently available evidence.
METHODS: Three databases were searched for comparative studies on this topic by using relevant keywords of ACS and morphine. Two authors independently extracted study information, mortality, major adverse cardiac event (MACE), major bleeding, and length of hospital stay. Then, they evaluated the quality of evidence independently. Meta-analysis was planned to be conducted in random-effects model. Risk ratio (RR) was used for most outcomes except hospital stay, and Peto odds ratio (POR) was used if there were any zero cells. Pooled estimate was presented with 95% confidence interval (CI).
RESULTS: Fourteen studies (n = 73,033) met eligibility criteria, and there was non-significant difference in mortality between antiplatelet with and without morphine (RR = 1.13, 95%CI: 0.78 to 1.64). Antiplatelet therapy without morphine significantly reduced the risk of MACE (RR = 0.78, 95%CI: 0.67 to 0.89; I-square = 0%), but increased the odds of major bleeding (POR = 1.87, 95%CI: 1.04 to 3.35; I-square = 0%) as compared with the combined use of antiplatelet therapy and morphine.
CONCLUSION: In conclusion, there is no statistically significant difference in mortality in patients with ACS using morphine or not, but clinicians ought to make a trade-off between a lower risk of MACE and a higher risk of major bleeding before adding morphine to antiplatelet therapy.
参考来源
- Lee SW, Kuo N, Hou SK, et al. Effects of morphine and P2Y inhibitor amongst patients with acute coronary syndrome: A meta-analysis of comparative studies. Am J Emerg Med. 2023. PMID: 37270851. doi:10.1016/j.ajem.2023.05.010
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。